Ask AI
ProCE Banner Activity

Elevating Tardive Dyskinesia Detection and Care: Comprehensive Strategies for APP

Slideset

Download this slideset resource for an APP-focused overview of the prevalence and burden of tardive dyskinesia, patient risk factors affecting screening recommendations, a step-by-step breakdown of symptom assessment using the Abnormal Involuntary Movement Scale (AIMS), and guidance for FDA-approved treatment with VMAT2 inhibitors.

Released: May 05, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences.

Neurocrine Biosciences

Target Audience

This educational activity is intended for psychiatrists, geriatricians, neurologists, nurse practitioners, physician associates, general and family practice physicians, long-term care pharmacists, psychologists, social workers, and other healthcare professionals who treat patients or advise HCP care teams regarding their patients with tardive dyskinesia who may benefit from this education.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize patient- and treatment-related risk factors for tardive dyskinesia across adult populations

  • Implement routine TD screening using validated assessment tools, such as the Abnormal Involuntary Movement Scale (AIMS), to support early identification and ongoing monitoring within clinical workloads

  • Apply evidence-based, patient-centered approaches to TD management and referral, incorporating shared decision-making, collaboration with specialists, and consideration of functional impact and psychiatric stability